You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Review: Antipsychotic plus mood stabiliser co-therapy is more effective than mood stabiliser mono-therapy at reducing acute bipolar mania

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: Antipsychotic plus mood stabiliser co-therapy is more effective than mood stabiliser mono-therapy at reducing acute bipolar mania

http://dx.doi.org/10.1136/ebmh.10.3.83

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Smith LA, Cornelius V, Warnock A, et al. Acute bipolar mania: a systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115:12–20.OpenUrlCrossRefPubMedWeb of Science

    Q How effective is co-therapy (an antipsychotic plus a mood stabiliser) compared with monotherapy (mood stabiliser alone) for people with bipolar mania?

    METHOD

    Embedded ImageDesign:

    Systematic review with meta-analysis.

    Embedded ImageData sources:

    MEDLINE, EMBASE, PsycINFO and Cochrane Central Register of Controlled Trials (searched March 2006).

    Embedded ImageStudy selection and analysis:

    Included studies were randomised controlled trials (RCTs) comparing co-therapy (an antipsychotic plus a mood stabiliser) versus monotherapy (mood-stabiliser alone) or another co-therapy for acute bipolar mania. Drugs had to be licensed in the UK or US for treatment of bipolar disorder (valproate semisodium, lithium, carbamazepine, lamotrigine, aripiprazole, olanzapine, risperidone, ziprasidone, quetiapine, haloperidol, chlorpromazine, flupentixol, fluphenazine, perphenazine, prochlorperazine and zuclopenthixol). Studies of mixed diagnostic groups were included if randomisation was stratified by bipolar …

    View Full Text

    Footnotes

    • For correspondence: Dr David Taylor, Pharmacy Department, Maudsley Hospital, South London and Maudsley NHS Trust, London, SE5 8AZ, UK; david.taylor{at}slam.nhs.uk

    • Source of funding: Sanofi Aventis.

    Footnotes

    • Competing interests: None declared.